Skip to Main Content

The Departments of Anesthesiology and Neurology hosts: “Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease”

February 12, 2020

The Departments of Anesthesiology and Neurology hosts: Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease

Perivascular space and cerebral small vessel disease mini-symposium March 24th in the Brady Memorial Auditorium 1:30-4:30pm

The panel will feature the following Speakers:

  • Joanna M. Wardlaw (Professor of Applied Neuroimaging and Director of Edinburgh Imaging, University of Edinburgh) “Perivascular Spaces in the Brain: Anatomy, Physiology, and Contributions to Pathology of Small Vessel Disease”
  • (Professor of Neurology and Neuroscience): “Optical Interrogation of Neurovascular and Myelin Pathophysiology in the Live Mammalian Brain”
  • (Professor of Anesthesiology): “Delayed cerebral ischemia in SAH - mechanisms and opportunities for intervention”
  • (Professor of Stroke Medicine, University of Nottingham): “Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions”

Speakers:

Joanna Wardlaw, MD FRCR FRCP FMedSci FRSE CBE

Professor of Applied Neuroimaging and

Director of Edinburgh Imaging

University of Edinburgh, UK

Jaime Grutzendler, MD

Professor of Neurology and Neuroscience

Director, Center for Experimental Neuroimaging

Yale School of Medicine, New Haven

Miriam Treggiari, MD, PhD, MPH

Professor of Anesthesiology, Vice Chair of Clinical Research, Yale School of Medicine, New Haven

Phillip Bath, M.D., F.R.C.P., FMedSci

Professor of Stroke Medicine

University of Nottingham, UK

Contacts: Jennifer Vissagio Jennifer.vissagio@yale.edu 203 785 3358

Host Organizations: Anesthesiology and Neurology

Precis: Cerebral small vessel disease (cSVD) are a group of disorders that result from pathological alteration of the small blood vessels in the brain and rank as the most common pathology in vascular dementia. Of the nearly 35-36 million people that are estimated to suffer from dementia worldwide, up to 65% have an cSVD component. Unfortunately, the prevalence of SVD is increasing and effective disease-modifying interventions are yet to be found. In recent years, there has been tremendous growth in new diagnostic information, a greater understanding of cSVD risk factors as well as instigation of new large clinical trials of repurposed drugs in cSVD to prevent dementia and stroke.

Moderator: Helene Benveniste, MD, PhD

Submitted by Garrett Sendlewski on February 12, 2020